by Raynovich Rod | Mar 7, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Diagnostics Companies-After 2013 Financial Reporting Stocks to Watch: Cepheid (CPHD), Exact Sciences (EXAS) , Orasure (OSUR) Price to Sales (P/S) is the best metric of value as many companies in the sector are not profitable. Molecular diagnostics and genomics are...
by Raynovich Rod | Mar 4, 2014 | Biopharmaceuticals
Stealth Biotech Sell-Off-Caution Urged-Red Screen Aegerion (AEGR $50) down 7%, Medivation (MDVN $66.9) off 5%, Puma (PBYI $113.5) off 5.4%, IBB ($261.75) off 2.8% , XBI ($161.9 off 3% etc. ———-from 5/4——– Most Biotech Stocks...
by Raynovich Rod | Feb 27, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Clinical Diagnostics and Tools
Rayno Life Science Movers -Diagnostics Review Next Week Despite some choppiness in biotech trading this week many of our stocks did well. I won’t go into some of the unusual volatility in other small and mid-caps lately but that is part of the reason for my...
by Raynovich Rod | Feb 25, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech May Be A Bubble-But What to Do? The blogosphere is trying to temper bullish sentiment with a lot of “bubble “talk even though the cable channels are still pumping biotech. If you have been around biotech for 25 years especially during the last...
by Raynovich Rod | Feb 18, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 2/21: Life Science stocks have blown through new highs this AM Large and mid-cap biopharma: ALKS BIIB,PCYC,REGN SGEN etc ETFs: IBB ($270) and XBI ($165) at new highs Two Rayno Dx laggard stocks on the move: RGDX and VRML. ———- Rayno Life...
by Raynovich Rod | Feb 14, 2014 | Biopharmaceuticals
Profit Taking On High Fliers- INCY, MDVN, PBYI, XBI Agilent(A) Growth Slows NASDAQ Flat at 4234 12:15p EST After hitting new highs this week biotech stocks are in a wave of selling so watch technicals and volume. The small cap, speculative weighted XBI ETF is down...
by Raynovich Rod | Feb 12, 2014 | Biopharmaceuticals
With Updates Today 2/13/14 XBI at $157.8 Biotechnology Bubblet- How High Can These Stocks Run? We reviewed mid-cap biopharmaceutical valuation in early October as part of our overall market model for a sector that defies classical analysis. Two emerging growth...
by Raynovich Rod | Feb 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Large Cap Biotechs Hover Near January 2014 Highs IBB At $254 on 2/11/14 The biotechnology sector has come roaring back after a 5-7% correction in February. Only one stock is at a new high Alexion (ALXN $171) . Many speculative mid and small caps are doing slightly...
by Raynovich Rod | Feb 9, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Life Science Stocks Surge Ahead From February Lows NASDAQ Up 1.67%, IBB Up 4%, FBIOX up 4.72%, XBI up 5.64%, XLV up 1.7% The soaring biotech sector would not let a losing week go by and took off early Friday erasing most losses for the week 2/3 to 2/7. Institutions...
by Raynovich Rod | Feb 5, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bull Market Intact But Technicals Rule On January 27 we reiterated our model for life science stocks for 2014. We will review each component of our model and where the sector stands after about a 5% correction off highs with the sector still up 6% YTD...
